Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14416597 | 0.89 | TSHR (0.61) | MAPTL3MBTL1TSHRCYP3A4NLRP3 | |
| SCHEMBL21681228 | 0.88 | TSHR (0.54) | MAPTL3MBTL1TSHRCYP3A4KDM4E | |
| SCHEMBL14416594 | 0.86 | TSHR (0.46) | MAPTL3MBTL1TSHRCYP3A4NLRP3 | |
| SCHEMBL11878688 | 0.83 | MAPT (0.46) | MAPTL3MBTL1CYP3A4NLRP3ALDH1A1 | |
| SCHEMBL11367094 | 0.83 | ALDH1A1 (0.60) | MAPTCYP3A4ALDH1A1POLBRAB9A | |
| SCHEMBL4368336 | 0.82 | KMT2A (0.50) | MAPTL3MBTL1TSHRCYP3A4KDM4E | |
| SCHEMBL7291906 | 0.82 | ALDH1A1 (0.61) | MAPTL3MBTL1NLRP3KDM4EALDH1A1 | |
| SCHEMBL14416633 | 0.81 | IAPP (0.50) | MAPTL3MBTL1TSHRCYP3A4NLRP3 | |
| SCHEMBL5803985 | 0.80 | MAPT (0.53) | MAPTL3MBTL1ALDH1A1TYK2 | |
| SCHEMBL5803983 | 0.80 | MAPT (0.49) | MAPTL3MBTL1NLRP3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2036548-A1 | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss | onepharm Research & Development GmbH (AT) | 2009-03-18 | — | — | EP | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20020010340-A1 | Process for preparation of 2-aminothiazolecarboxamide derivatives | LG CHEMICAL LTD. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010340-A1 | Process for preparation of 2-aminothiazolecarboxamide derivatives | CBR1, CBR3, CYP1B1 | MAPT 3731/4885L3MBTL1 4314/4885TSHR 1835/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | MAPT 3034/4885L3MBTL1 3206/4885TSHR 3829/4885 |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | OPRL1, OPRK1, OPRM1 | MAPT 4215/4885L3MBTL1 3486/4885TSHR 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.